# US 2022/0016058 A1 · Pharmaceutical composition containing tamsulosin hydrochloride with excellent acid resistance and preparation method therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0016058 A1
- Document ID: US20220016058A1
- Status: Published application
- Kind: A1
- Application number: 17/309,730
- Filed: 2019-11-25
- Published: 2022-01-20
- Earliest claimed: 2018-12-21
- Assignees: Hanmi Pharm. Co., Ltd.
- Applicants: Hanmi Pharm. Co., Ltd.
- Inventors: Eun Ho HA; Seung Jun LEE; Ho Taek IM; Yong II KIM
- Web page: https://patentgrep.com/patent/US20220016058A1

## CPC

- A61K 9/2081: {with microcapsules or coated microparticles according to A61K9/50}
- A61K 31/18: Sulfonamides (compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63)
- A61K 9/20: Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/50: Microcapsules {having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals (A61K9/2081 takes precedence; particles with a single coating comprising drug A61K9/167)}
- A61K 9/5026: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/5073: {having two or more different coatings optionally including drug-containing subcoatings}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed are an acid-resistant pharmaceutical composition including tamsulosin hydrochloride, and a method of preparing the same. The pharmaceutical composition is formulated into tablets by preparing core beads including tamsulosin hydrochloride as an active ingredient, coating the core beads with an entering coating solution including a specific amount of plasticizer, adding a post mixture portion including a buffer to adjust density and a lubricant to the enteric-coated core beads, and performing tableting. The enteric coating layer is not broken during the tableting process. Thus, the acid resistance of the pharmaceutical composition is maintained. The pharmaceutical composition can be easily formulated into tablets, ensures good uniformity of dosage unit, lowers dissolution rate of tamsulosin hydrochloride, has good acid resistance, and is stable not to exhibit signification decomposition of tamsulosin hydrochloride.

## Claims

### Claim 1

A pharmaceutical composition containing tamsulosin hydrochloride comprising: tamsulosin hydrochloride as an active ingredient; an enteric polymer; and a plasticizer, wherein the plasticizer is included in a content of 0.10% by weight to 3.5% by weight, based on the total amount of the pharmaceutical composition.

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the plasticizer is at least one or more substances selected from the group consisting of polyethylene glycol, polypropylene glycol, polyglycolic acid, poly(butylene adipate), glycerin, tributyl sebacate, triacetin, and triethyl citrate.

### Claim 3 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the enteric polymer is at least one or more acid-resistant acrylic polymer selected from the group consisting of a methacrylic acid-methyl methacrylate copolymer and a methacrylic acid-ethyl acrylate copolymer.

### Claim 4 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition has a dissolution rate of 20% or lower after 2 hours when the dissolution rate is measured with a pH 1.2 buffer solution of 500 mL at a rotation speed of 75 rpm according to the USP dissolution test method 2 (paddle method).

### Claim 5 (depends on 1)

The pharmaceutical composition according to claim 1, further comprising: a sustained-releasing agent.

### Claim 6 (depends on 5)

The pharmaceutical composition according to claim 5, wherein the sustained-releasing agent is at least one or more selected from the group consisting of polyvinyl acetate, a mixture including polyvinyl acetate, ethylcellulose, and hydroxypropylmethylcellulose (HPMC).

### Claim 7 (depends on 1)

The pharmaceutical composition according to claim 1, further comprising: a disintegrant, a buffer, or both.

### Claim 8 (depends on 7)

The pharmaceutical composition according to claim 7, wherein the buffer is colloidal silicon dioxide, and comprising a content of 0.50% by weight to 3.0% by weight based on the total amount of the pharmaceutical composition.

### Claim 9 (depends on 1)

The pharmaceutical composition according to claim 1, further comprising: a lubricant.

### Claim 10 (depends on 9)

The pharmaceutical composition according to claim 9, wherein the lubricant is magnesium stearate has a content of less than 3% by weight based on the total amount of pharmaceutical composition.

### Claim 11 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the composition is formulated into tablets by coating sustained-release core beads including tamsulosin hydrochloride and a sustained-releasing agent with an enteric coating solution including an enteric polymer and a plasticizer, after mixing the coated core beads with a post mixture including a disintegrant and a buffer, and tableting the obtained mixture.

### Claim 12

A method of preparing a pharmaceutical composition containing tamsulosin hydrochloride is composed of:
preparing core beads comprising tamsulosin hydrochloride;
preparing sustained-release core beads by coating the core bead with a sustained-release coating solution including a sustained-releasing agent;
preparing enteric-coated sustained-release core beads having an enteric coating layer by coating the sustained-release core beads with an enteric coating solution including an enteric polymer and a plasticizer;
preparing a post mixture including a disintegrant and a buffer;
after mixing the enteric-coated sustained-release core beads, the post mixture, and a lubricant, and tableting the obtained mixture.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the preparing of the sustained-release core beads is comprised of preparing core beads including tamsulosin hydrochloride, a binder, and a diluent, and then coating the core beads with a sustained-release coating solution including a sustained-releasing agent.

### Claim 14 (depends on 12)

The method according to claim 12, wherein the plasticizer is at least one or more substances selected from the group consisting of polyethylene glycol, polypropylene glycol, polyglycolic acid, poly(butylene adipate), glycerin, tributyl sebacate, triacetin, and triethyl citrate.

### Claim 15 (depends on 12)

The method according to claim 12, wherein the post mixture has an apparent density of 0.40 mg/mL to 0.52 mg/mL.

### Claim 16 (depends on 12)

The method according to claim 12, wherein the pharmaceutical composition is formulated into tablets.
